Clinical trials: Seizures Disorders
Epilepsy, Seizures
University of Alabama at Birmingham (UAB) Pediatric CBD Program
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.
- Trial name
- NCT02695537
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Alabama at Birmingham
Partial Epilepsy
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy…
- Trial name
- NCT00957047
- Testing
- eslicarbazepine acetate, ESL - Part II
- Where
- Portugal
- Volunteers
- 395 people
- Sponsor
- Bial - Portela C S.A.
Partial Seizures
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration…
- Trial name
- PREPS MEXICO (NCT00407797)
- Testing
- Pregabalin
- Where
- 8 sites in Mexico
- Volunteers
- 136 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Photosensitive Epilepsy
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
The primary purpose of the study is to assess the pharmacodynamic (PD) activity of E2730 as measured by suppression of epileptic photoparoxysmal response (PPR) in the participant's most sensitive eye condition in participants…
- Trial name
- NCT03603639
- Testing
- E2730
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Epilepsies, Partial
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures.
- Trial name
- NCT00524030
- Testing
- pregabalin 600 mg/day, pregabalin 150 mg/day
- Where
- 73 sites in United States, Czechia and 2 more
- Volunteers
- 161 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Highly Drug-resistant Focal Epilepsy
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy.
- Trial name
- NCT02625090
- Testing
- UCB0942
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 42 people
- Sponsor
- UCB Biopharma SRL
Status Epilepticus
SURESTEP: Transcranial Direct Current Stimulation in Super Refractory Status Epilepticus
The purpose of this study is to determine whether transcranial direct current stimulation affects super refractory status epilepticus.
- Trial name
- SURESTEP (NCT03819543)
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Seizures, Urticaria and Angioedema
A Safety Study For Prevenar 13 Among Chinese Children
This is an observational study based on a population-based EHR database.
- Conditions
- Seizures, Urticaria and Angioedema, Apnea, Fever
- Trial name
- NCT03656939
- Where
- China
- Volunteers
- 21,240 people
- Sponsor
- Pfizer
Primary Generalized Epilepsy
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures.
- Trial name
- NCT03678753
- Testing
- Cenobamate
- Where
- 116 sites in United States, Australia and 10 more
- Volunteers
- 169 people
- Sponsor
- SK Life Science, Inc.
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Brain Tumor
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
The main purpose of this part of the study is to determine the Central Nervous System bioavailability of sulfasalazine.
- Trial name
- NCT01577966
- Testing
- Sulfasalazine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Seizures
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three…
- Trial name
- RESTORE1 (NCT00232596)
- Testing
- Retigabine
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on…
- Trial name
- NCT01229735
- Testing
- Levetiracetam, Topiramate
- Where
- 24 sites in South Korea
- Volunteers
- 343 people
- Sponsor
- UCB Korea Co., Ltd.
Ear Diseases, Hearing Loss, Bilateral
Lumity CI Study - Clinical Evaluation of Next Generation Cochlear Implant Sound Processor
This is a prospective within-subjects repeated-measures study that will enroll 18 bilateral adult users implanted with a HiResolution Bionic Ear System (HiRes 90KTM, HiRes 90K TM Advantage, HiResTM Ultra, HiResTM Ultra 3D and CII…
- Conditions
- Ear Diseases, Hearing Loss, Bilateral, Otorhinolaryngologic Diseases
- Trial name
- NCT06858826
- Testing
- Control cochlear implant sound processor, Next Generation Sound Processor
- Volunteers
- 20 people
- Sponsor
- Advanced Bionics
Status Epilepticus
LORA-PITA IV General Investigation
Secondary Data Collection:To confirm the effectiveness and safety profiles under the actual medical practice of LORA-PITA in Japan.
- Trial name
- NCT03905798
- Testing
- Lorazepam
- Where
- Japan
- Volunteers
- 206 people
- Sponsor
- Pfizer
Electroencephalographic Neonatal Seizures
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the…
- Trial name
- NCT03325439
- Testing
- Brivaracetam (BRV) intravenous (iv), Brivaracetam (BRV) oral
- Where
- 12 sites in Belgium, Czechia and 5 more
- Volunteers
- 9 people
- Sponsor
- UCB Biopharma SRL
Epilepsy
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
- Trial name
- NCT02161185
- Testing
- USL261
- Where
- 16 sites in United States
- Volunteers
- 7 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Conversion Disorder
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Nonepileptic Seizures, Functional Movement Disorders and Functional Weakness.
- Trial name
- NCT03398070
- Testing
- Standard of Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Traumatic Brain Injury
Effects of Huperzine A in Treatment of Moderate to Severe TBI
We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after…
- Trial name
- NCT01676311
- Testing
- Huperzine A
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Spaulding Rehabilitation Hospital